Ocugen, Inc. (OCGN) Stock Grade

About Ocugen, Inc.'s fundamentals

Ocugen is a biotechnology company with a market capitalization of $349.3 million that generated 8.8% year-over-year revenue growth in its latest period. However, the company reported a substantial net loss, resulting in a net margin of -1537.4%, which means it is currently unprofitable and burning through capital. The company does not pay a dividend, and traditional valuation metrics like P/E ratio are not applicable due to the net loss. This financial profile is typical for early-stage biotech firms investing heavily in research and development before achieving profitability.